Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
Clinical trial NCT05222932 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05222932
- Sponsor
- TILT Biotherapeutics Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-08
- Primary completion
- 2026-12-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.